DDInter898 DDInter856
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Ibritumomab tiuxetan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Antithrombin Alfa
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Abciximab
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Abciximab
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketorolac